An overview on 2-indolinone derivatives as anticancer agents
| Autor: | Samy M. Ibrahim, Ahmed S. Abdelkhalek, Shaban A. A. Abdel-Raheem, Nada E. Freah, Nada H. El Hady, Nada K. Aidia, Nada A. Tawfeq, Nora I. Gomaa, Nora M. Fouad, Hager A. Salem, Hager M. Ibrahim, Mahmoud M. Sebai |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Current Chemistry Letters, Vol 13, Iss 1, Pp 241-254 (2024) |
| Druh dokumentu: | article |
| ISSN: | 1927-7296 1927-730X |
| DOI: | 10.5267/j.ccl.2023.6.005 |
| Popis: | 2-Indolinone nucleus is considered one of a promising heterocyclic core in medicinal chemistry that showed numerous range of activity among which antimicrobial, antioxidant, antiviral, antitubercular and anticancer activities. Cancer targeting is still an issue so there is a need for developing new agents that inhibit cancer growth without or low effect on normal body cells. Some derivatives of indolin-2-one are known to be a critical structure in some inhibitors of receptor tyrosine kinases (RTKs); a cancer target therapy, for example, Sunitinib. Herein in this review we focus on 2-indolinone derivatives as RTKs inhibitors as cancer targeting therapy. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|